Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 52 No. 3 › Psychopharmacotherapy of Premenstrual...
REVIEW ARTICLE

Psychopharmacotherapy of Premenstrual Dysphoric Disorder—New Vistas

Ahmed Naguy, Adel El-Sheshai, Sri Haricharan Thiguti, Bibi Alamiri
Psychopharmacology Bulletin 52(3): 81-83, 2022/06/27; https://doi.org/10.64719/pb.4447

Abstract

Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.

Keywords

allopregnanolone, PMDD, psychopharmacology

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In
Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Ahmed Naguy, Adel El-Sheshai, Sri Haricharan Thiguti, Bibi Alamiri. Psychopharmacotherapy of Premenstrual Dysphoric Disorder—New Vistas. Psychopharmacology Bulletin. 2022/06/27; 52(3):81-83. https://doi.org/10.64719/pb.4447